Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target decreased by Bank of America from $61.00 to $47.00 ...
According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price ...
Stock Index Futures Gain With U.S. Presidential Election in Focus, Economic Data and Earnings on Tap
Asian stock markets today settled in the green ... Northern Oil&Gas (NOG), Newmark Group (NMRK), National Health Investors (NHI), Apellis Pharma (APLS), Payoneer Global Inc (PAYO), Consol Energy (CEIX ...
Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...
Mizuho Securities analyst Graig Suvannavejh has maintained their neutral stance on APLS stock, giving a Hold rating on November 4. Graig ...
Stifel Nicolaus analyst Annabel Samimy has maintained their bullish stance on APLS stock, giving a Buy rating today. Annabel Samimy’s ...
Apellis unveiled those results before market hours on Tuesday, disclosing that its revenue for the quarter was just under $197 million. That was ...
On Friday, Apellis Pharmaceuticals Inc (APLS) stock saw a modest uptick, ending the day at $27.98 which represents a slight increase of $0.72 or 2.64% from the prior close of $27.26. The stock opened ...
Check the time stamp on this data. Updated AI-Generated Signals for Apellis Pharmaceuticals Inc. (APLS) available here: APLS.
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models. Tips that distill complex financial data into concise, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback